Vol 17, No 4 2019
Kidney Cancer Journal Author Guidelines
Scope of Manuscripts
Kidney Cancer Journal considers the following types of manuscripts for publication:
Authors are required to submit their manuscripts in an electronic format, preferably by email to the Editor-in-Chief, Robert A. Figlin, MD, at email@example.com. Please provide as a Microsoft Word document. Images should be submitted electronically as well.
All material reproduced from previously published, copyrighted material should contain a full credit line acknowledging the original source. The author is responsible for obtaining this permission
List all authors, including mailing address, titles and affiliations, phone, fax, and email. Please note corresponding author.
Peer Review and Editing
Manuscripts will be peer reviewed. Accepted manuscripts will be edited for clarity, spelling, punctuation, grammar, and consistency with American Medical Association (AMA) style. Authors whose manuscripts are not initially accepted may have the opportunity to revise the manuscript based on recommendations from peer reviewers and at the discretion of the Editor-in-Chief.
Conflict of Interest
Kidney Cancer Journal policy requires that authors reveal to the Editor-in-Chief any relationships that they believe could be construed as resulting in an actual, potential, or apparent conflict of interest with regard to the manuscript submitted for review. Authors must disclose this information in the covering letter accompanying their submission.
Length: Full-length manuscripts should not exceed 4,000 words, including references. Please limit the reference list to 50 citations. Manuscripts should be accompanied by figures and/or tables. Generally 4-5 figures and 2-3 tables are preferred for each manuscript. Please include a brief description to accompany these items, as well as a legend for all abbreviations. Manuscripts should not contain an abstract but an introduction is recommended.
Spacing: One space after periods. Manuscripts should be double spaced.
All submissions should have references that are referred to in the text by superscripted numbers and that conform to AMA style.
Lewczuk J, Piszko P, Jagas J, et al. Prognostic factors in medically treated patients with chronic pulmonary embolism. Chest. 2001;119:818-823.
Manuscripts and accompanying material are accepted for exclusive publication in the Kidney Cancer Journal. None of the contents may be reproduced without permission of the Kidney Cancer Journal.
To request permission, please contact Senthil Samy at firstname.lastname@example.org
+1 (919) 694-3599
As an official publication of the Kidney Cancer Association, Kidney Cancer Journal (KCJ) is committed to maintaining the highest standards of publication ethics and abides by Code of Conduct of Committee on Publication Ethics (COPE), and aims to adhere to its Best Practice Guidelines. Please refer to COPE flowcharts for further guidance.
Manuscript authors, editors, and reviewers are expected to be aware of, and comply with, the best practices in publication ethics. Authors are expected to have knowledge of best practice in publication ethics in regard to, but not limited to, authorship, dual submission, plagiarism, manipulation of data/figures, competing interests and compliance with policies on research ethics. Reviewers and editors are required to treat manuscripts fairly and in confidence, and to declare any competing interests. Authors are obligated to disclose potential bioethics/dual use concerns to the journal office at the time of initial submission. Editors and reviewers are expected to evaluate potential risks and alert the journal with any concerns.
We reserve the right to contact authors’ institutions, funding agencies or regulatory bodies if required and we would investigate research allegations or publication misconduct per COPE guidelines. If you have any concerns about potential misconduct, please email the journal. Address correspondence to the journal’s Editor-in-Chief or Executive Editor as appropriate.
Plagiarism is not acceptable in KCJ submissions and plagiarized content will not be considered for publication per COPE guidelines. We reserve the right to inform authors' institutions about plagiarism detected either before or after publication.
All submitted material should be treated as strictly confidential until published. The peer review process is confidential to all parties. Correspondence as part of the review process is also to be treated confidentially by all parties, including authors.
Editors and reviewers are required to treat all submitted manuscripts in strict confidence and should not share information about submissions with any other parties unless previously agreed with the editor. Any third party involvement in the review must be declared at the time of the submission of the review. We will follow COPE guidelines in investigating any concerns about misconduct during the review process.
Upon submission of a manuscript, authors must indicate whether there are any related manuscripts under consideration or published elsewhere. If related work has been submitted or published elsewhere, authors must include a copy of it with their submission and describe its relation to the submitted work. Prior publication of research as a thesis, presentation at medical or scientific conferences, or posting on preprint servers will not preclude consideration of your manuscript. Image files should not be manipulated or adjusted in any way that could lead to misinterpretation of the information present in the original image.
Editor and reviewer requirements
Reviewers and editors should evaluate any related content and notify the journal of overlap. Editors and reviewers should alert the journal if they identify duplicate submissions or publications during the review process.
KCJ follows standards set by national and public agencies. Individual research projects will be subject to appropriate ethical consideration and approval and if necessary individuals will be contacted for specific consent to participate.
Duplicate content discovered after publication will be addressed depending on the degree of overlap. The journal may issue a correction or a retraction as appropriate.
Policy on use of human subjects
The clinical research studies involving the use of human subjects should inform that study has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed. Patients' and volunteers' names, initials, and hospital numbers should not be used.
Policy on use of animals
Studies involving experiments with animals must state that their care was in accordance with institution guidelines. All animal experiments should comply with the appropriate standard guidelines/act for the care and use of Laboratory animals and the authors should clearly indicate in the manuscript that such guidelines have been followed. Studies involving experiments with animals must state that their care was in accordance with institution guidelines.
Authors must state in their manuscript how the identity of the cell line was confirmed.
Copyright © 2020